vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与VIEMED HEALTHCARE, INC.（VMD）财务数据对比。点击上方公司名可切换其他公司
VIEMED HEALTHCARE, INC.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.0倍（$76.2M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 25.5%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $9.7M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 22.7%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
Viemed Healthcare是一家专注于呼吸护理解决方案的医疗科技企业，研发、生产及销售便携式呼吸机、呼吸治疗设备及配套支持服务，覆盖北美、欧洲及亚太核心市场的急症、亚急症及居家护理场景，服务急慢性呼吸系统疾病患者。
PBYI vs VMD — 直观对比
营收规模更大
VMD
是对方的1.0倍
$75.5M
营收增速更快
PBYI
高出2.2%
25.5%
自由现金流更多
PBYI
多$4.7M
$9.7M
两年增速更快
PBYI
近两年复合增速
22.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $76.2M |
| 净利润 | — | $5.6M |
| 毛利率 | 69.3% | 57.9% |
| 营业利润率 | 22.7% | 11.0% |
| 净利率 | — | 7.4% |
| 营收同比 | 27.7% | 25.5% |
| 净利润同比 | — | 30.7% |
| 每股收益（稀释后） | $0.26 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIVMD
| Q4 25 | $75.5M | $76.2M | ||
| Q3 25 | $54.5M | $71.9M | ||
| Q2 25 | $52.4M | $63.1M | ||
| Q1 25 | $46.0M | $59.1M | ||
| Q4 24 | $59.1M | $60.7M | ||
| Q3 24 | $80.5M | $58.0M | ||
| Q2 24 | $47.1M | $55.0M | ||
| Q1 24 | $43.8M | $50.6M |
净利润PBYIVMD
| Q4 25 | — | $5.6M | ||
| Q3 25 | $8.8M | $3.5M | ||
| Q2 25 | $5.9M | $3.2M | ||
| Q1 25 | $3.0M | $2.6M | ||
| Q4 24 | — | $4.3M | ||
| Q3 24 | $20.3M | $3.9M | ||
| Q2 24 | $-4.5M | $1.5M | ||
| Q1 24 | $-4.8M | $1.6M |
毛利率PBYIVMD
| Q4 25 | 69.3% | 57.9% | ||
| Q3 25 | 77.7% | 57.5% | ||
| Q2 25 | 76.5% | 58.3% | ||
| Q1 25 | 77.1% | 56.3% | ||
| Q4 24 | 76.4% | 59.5% | ||
| Q3 24 | 63.9% | 59.3% | ||
| Q2 24 | 77.4% | 59.8% | ||
| Q1 24 | 75.5% | 58.9% |
营业利润率PBYIVMD
| Q4 25 | 22.7% | 11.0% | ||
| Q3 25 | 17.6% | 7.8% | ||
| Q2 25 | 12.7% | 8.1% | ||
| Q1 25 | 8.7% | 6.5% | ||
| Q4 24 | 22.6% | 10.6% | ||
| Q3 24 | 27.4% | 9.7% | ||
| Q2 24 | -4.6% | 6.6% | ||
| Q1 24 | -5.3% | 4.4% |
净利率PBYIVMD
| Q4 25 | — | 7.4% | ||
| Q3 25 | 16.2% | 4.9% | ||
| Q2 25 | 11.2% | 5.0% | ||
| Q1 25 | 6.5% | 4.4% | ||
| Q4 24 | — | 7.1% | ||
| Q3 24 | 25.2% | 6.7% | ||
| Q2 24 | -9.6% | 2.7% | ||
| Q1 24 | -11.0% | 3.2% |
每股收益（稀释后）PBYIVMD
| Q4 25 | $0.26 | $0.14 | ||
| Q3 25 | $0.17 | $0.09 | ||
| Q2 25 | $0.12 | $0.08 | ||
| Q1 25 | $0.06 | $0.06 | ||
| Q4 24 | $0.40 | $0.10 | ||
| Q3 24 | $0.41 | $0.10 | ||
| Q2 24 | $-0.09 | $0.04 | ||
| Q1 24 | $-0.10 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $13.5M |
| 总债务越低越好 | $22.7M | — |
| 股东权益账面价值 | $130.3M | $141.5M |
| 总资产 | $216.3M | $199.2M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYIVMD
| Q4 25 | $97.5M | $13.5M | ||
| Q3 25 | $94.4M | $11.1M | ||
| Q2 25 | $96.0M | $20.0M | ||
| Q1 25 | $93.2M | $10.2M | ||
| Q4 24 | $101.0M | $17.5M | ||
| Q3 24 | $96.7M | $11.3M | ||
| Q2 24 | $96.8M | $8.8M | ||
| Q1 24 | $107.2M | $7.3M |
总债务PBYIVMD
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
股东权益PBYIVMD
| Q4 25 | $130.3M | $141.5M | ||
| Q3 25 | $115.3M | $133.6M | ||
| Q2 25 | $104.7M | $139.7M | ||
| Q1 25 | $97.1M | $134.8M | ||
| Q4 24 | $92.1M | $131.4M | ||
| Q3 24 | $71.1M | $125.0M | ||
| Q2 24 | $48.5M | $119.4M | ||
| Q1 24 | $51.0M | $116.3M |
总资产PBYIVMD
| Q4 25 | $216.3M | $199.2M | ||
| Q3 25 | $202.9M | $202.4M | ||
| Q2 25 | $194.9M | $184.6M | ||
| Q1 25 | $196.2M | $178.1M | ||
| Q4 24 | $213.3M | $177.1M | ||
| Q3 24 | $220.7M | $169.5M | ||
| Q2 24 | $205.0M | $163.9M | ||
| Q1 24 | $214.1M | $154.9M |
负债/权益比PBYIVMD
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $18.4M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $9.7M |
| 自由现金流率自由现金流/营收 | 19.1% | 12.7% |
| 资本支出强度资本支出/营收 | 0.0% | 11.5% |
| 现金转化率经营现金流/净利润 | — | 3.27× |
| 过去12个月自由现金流最近4个季度 | $41.7M | $11.9M |
8季度趋势，按日历期对齐
经营现金流PBYIVMD
| Q4 25 | $14.4M | $18.4M | ||
| Q3 25 | $9.7M | $18.4M | ||
| Q2 25 | $14.1M | $12.3M | ||
| Q1 25 | $3.6M | $2.9M | ||
| Q4 24 | $15.6M | $15.0M | ||
| Q3 24 | $11.0M | $12.7M | ||
| Q2 24 | $1.0M | $10.2M | ||
| Q1 24 | $11.2M | $1.2M |
自由现金流PBYIVMD
| Q4 25 | $14.4M | $9.7M | ||
| Q3 25 | $9.7M | $10.7M | ||
| Q2 25 | $14.1M | $4.1M | ||
| Q1 25 | $3.6M | $-12.6M | ||
| Q4 24 | $15.6M | $3.2M | ||
| Q3 24 | $11.0M | $1.7M | ||
| Q2 24 | $1.0M | $1.2M | ||
| Q1 24 | — | $-4.8M |
自由现金流率PBYIVMD
| Q4 25 | 19.1% | 12.7% | ||
| Q3 25 | 17.7% | 14.9% | ||
| Q2 25 | 26.8% | 6.5% | ||
| Q1 25 | 7.7% | -21.4% | ||
| Q4 24 | 26.4% | 5.2% | ||
| Q3 24 | 13.7% | 3.0% | ||
| Q2 24 | 2.1% | 2.3% | ||
| Q1 24 | — | -9.5% |
资本支出强度PBYIVMD
| Q4 25 | 0.0% | 11.5% | ||
| Q3 25 | 0.0% | 10.6% | ||
| Q2 25 | 0.0% | 12.9% | ||
| Q1 25 | 0.1% | 26.2% | ||
| Q4 24 | 0.0% | 19.5% | ||
| Q3 24 | 0.0% | 19.0% | ||
| Q2 24 | 0.0% | 16.3% | ||
| Q1 24 | 0.0% | 11.9% |
现金转化率PBYIVMD
| Q4 25 | — | 3.27× | ||
| Q3 25 | 1.10× | 5.23× | ||
| Q2 25 | 2.41× | 3.88× | ||
| Q1 25 | 1.21× | 1.09× | ||
| Q4 24 | — | 3.47× | ||
| Q3 24 | 0.54× | 3.29× | ||
| Q2 24 | — | 6.94× | ||
| Q1 24 | — | 0.73× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
